Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma

Y. Baba, H. Saeki, Y. Nakashima, E. Oki, H. Shigaki, N. Yoshida, M. Watanabe, Y. Maehara, Hideo Baba

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

The predominant histological types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. Since these two histological types present as different diseases in terms of their epidemiology, pathologenesis, and tumor biology, separate therapeutic approaches should be developed against each type. While surgical resection remains the dominant therapeutic intervention for patients with operable esophageal squamous cell carcinoma (ESCC), their high rates of tumor recurrence have prompted investigation of multimodality therapies that combine surgery with chemotherapy, radiotherapy, and chemoradiotherapy. In Japan, preoperative chemotherapy with cisplatin (CDDP) plus 5-fluorouracil (5-FU) followed by radical esophagectomy has been accepted as the standard therapeutic approach for resactable clinical Stage II/III ESCC. Similarly, the CDDP and 5-FU regimen has been accepted as the first-line treatment for metastatic and unresectable ESCCs in Japan. Thus, in Japan chemotherapy is an indispensable component of therapy for both resectable and unresectable ESCCs. This review discusses the current knowledge, rationale, and available data regarding chemotherapy for resectable and unresectable ESCCs.

Original languageEnglish
Article number12521
JournalDiseases of the Esophagus
Volume30
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Drug Therapy
Japan
Fluorouracil
Therapeutics
Esophagectomy
Chemoradiotherapy
Esophageal Neoplasms
Cisplatin
Esophageal Squamous Cell Carcinoma
Squamous Cell Carcinoma
Neoplasms
Epidemiology
Adenocarcinoma
Radiotherapy
Recurrence

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma. / Baba, Y.; Saeki, H.; Nakashima, Y.; Oki, E.; Shigaki, H.; Yoshida, N.; Watanabe, M.; Maehara, Y.; Baba, Hideo.

In: Diseases of the Esophagus, Vol. 30, No. 2, 12521, 01.02.2017.

Research output: Contribution to journalReview article

Baba, Y. ; Saeki, H. ; Nakashima, Y. ; Oki, E. ; Shigaki, H. ; Yoshida, N. ; Watanabe, M. ; Maehara, Y. ; Baba, Hideo. / Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma. In: Diseases of the Esophagus. 2017 ; Vol. 30, No. 2.
@article{2c5f9547cf2f48a2ac69029ebe6af791,
title = "Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma",
abstract = "The predominant histological types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. Since these two histological types present as different diseases in terms of their epidemiology, pathologenesis, and tumor biology, separate therapeutic approaches should be developed against each type. While surgical resection remains the dominant therapeutic intervention for patients with operable esophageal squamous cell carcinoma (ESCC), their high rates of tumor recurrence have prompted investigation of multimodality therapies that combine surgery with chemotherapy, radiotherapy, and chemoradiotherapy. In Japan, preoperative chemotherapy with cisplatin (CDDP) plus 5-fluorouracil (5-FU) followed by radical esophagectomy has been accepted as the standard therapeutic approach for resactable clinical Stage II/III ESCC. Similarly, the CDDP and 5-FU regimen has been accepted as the first-line treatment for metastatic and unresectable ESCCs in Japan. Thus, in Japan chemotherapy is an indispensable component of therapy for both resectable and unresectable ESCCs. This review discusses the current knowledge, rationale, and available data regarding chemotherapy for resectable and unresectable ESCCs.",
author = "Y. Baba and H. Saeki and Y. Nakashima and E. Oki and H. Shigaki and N. Yoshida and M. Watanabe and Y. Maehara and Hideo Baba",
year = "2017",
month = "2",
day = "1",
doi = "10.1111/dote.12521",
language = "English",
volume = "30",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma

AU - Baba, Y.

AU - Saeki, H.

AU - Nakashima, Y.

AU - Oki, E.

AU - Shigaki, H.

AU - Yoshida, N.

AU - Watanabe, M.

AU - Maehara, Y.

AU - Baba, Hideo

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The predominant histological types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. Since these two histological types present as different diseases in terms of their epidemiology, pathologenesis, and tumor biology, separate therapeutic approaches should be developed against each type. While surgical resection remains the dominant therapeutic intervention for patients with operable esophageal squamous cell carcinoma (ESCC), their high rates of tumor recurrence have prompted investigation of multimodality therapies that combine surgery with chemotherapy, radiotherapy, and chemoradiotherapy. In Japan, preoperative chemotherapy with cisplatin (CDDP) plus 5-fluorouracil (5-FU) followed by radical esophagectomy has been accepted as the standard therapeutic approach for resactable clinical Stage II/III ESCC. Similarly, the CDDP and 5-FU regimen has been accepted as the first-line treatment for metastatic and unresectable ESCCs in Japan. Thus, in Japan chemotherapy is an indispensable component of therapy for both resectable and unresectable ESCCs. This review discusses the current knowledge, rationale, and available data regarding chemotherapy for resectable and unresectable ESCCs.

AB - The predominant histological types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. Since these two histological types present as different diseases in terms of their epidemiology, pathologenesis, and tumor biology, separate therapeutic approaches should be developed against each type. While surgical resection remains the dominant therapeutic intervention for patients with operable esophageal squamous cell carcinoma (ESCC), their high rates of tumor recurrence have prompted investigation of multimodality therapies that combine surgery with chemotherapy, radiotherapy, and chemoradiotherapy. In Japan, preoperative chemotherapy with cisplatin (CDDP) plus 5-fluorouracil (5-FU) followed by radical esophagectomy has been accepted as the standard therapeutic approach for resactable clinical Stage II/III ESCC. Similarly, the CDDP and 5-FU regimen has been accepted as the first-line treatment for metastatic and unresectable ESCCs in Japan. Thus, in Japan chemotherapy is an indispensable component of therapy for both resectable and unresectable ESCCs. This review discusses the current knowledge, rationale, and available data regarding chemotherapy for resectable and unresectable ESCCs.

UR - http://www.scopus.com/inward/record.url?scp=85005877115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005877115&partnerID=8YFLogxK

U2 - 10.1111/dote.12521

DO - 10.1111/dote.12521

M3 - Review article

C2 - 27868285

AN - SCOPUS:85005877115

VL - 30

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

IS - 2

M1 - 12521

ER -